Author's Reply to Wendling and Prati: “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs”

Drugs ◽  
2014 ◽  
Vol 74 (14) ◽  
pp. 1717-1718
Author(s):  
James Cheng-Chung Wei
Keyword(s):  
Clinical Trial ◽  
Treat To Target ◽  
Clinical Trial Designs

Comment on “Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs”

Drugs ◽  
2014 ◽  
Vol 74 (14) ◽  
pp. 1715-1716 ◽  
Author(s):  
Daniel Wendling ◽  
Clément Prati
Keyword(s):  
Clinical Trial ◽  
Treat To Target ◽  
Clinical Trial Designs

Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs

Drugs ◽  
2014 ◽  
Vol 74 (10) ◽  
pp. 1091-1096 ◽  
Author(s):  
James Cheng-Chung Wei
Keyword(s):  
Clinical Trial ◽  
Treat To Target ◽  
Clinical Trial Designs

scholarly journals New clinical trial designs for HIV vaccine evaluation

2013 ◽  
Vol 8 (5) ◽  
pp. 437-442 ◽  
Author(s):  
Zoe Moodie ◽  
Holly Janes ◽  
Yunda Huang
Keyword(s):  
Clinical Trial ◽  
Hiv Vaccine ◽  
Clinical Trial Designs

Current Advances in Clinical Trials for Rare Disease Populations: Spotlight on the Patient

2021 ◽  
Vol 16 ◽  
Author(s):  
Erica Winter ◽  
Scott Schliebner
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Drug Development ◽  
Rare Disease ◽  
Rare Diseases ◽  
Statistical Analyses ◽  
Clinical Trial Designs ◽  
Novel Approaches

: Characterized by small, highly heterogeneous patient populations, rare disease trials magnify the challenges often encountered in traditional clinical trials. In recent years, there have been increased efforts by stakeholders to improve drug development in rare diseases through novel approaches to clinical trial designs and statistical analyses. We highlight and discuss some of the current and emerging approaches aimed at overcoming challenges in rare disease clinical trials, with a focus on the ultimate stakeholder, the patient.

scholarly journals Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

2017 ◽  
Vol 28 (11) ◽  
pp. 2882-2887 ◽  
Author(s):  
D. Sellami ◽  
B. Dharan ◽  
C. Wilke ◽  
S.J. Scherer ◽  
S. Hirawat
Keyword(s):  
Clinical Trial ◽  
Circulating Tumor Dna ◽  
Pi3k Inhibitors ◽  
Clinical Trial Designs ◽  
Tumor Dna
Sign in / Sign up

Export Citation Format

Share Document